Patents by Inventor Napoleone Ferrara

Napoleone Ferrara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions with hematopoietic and immune activity
    Patent number: 8858936
    Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: October 14, 2014
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer LeCouter
  • Anti-BV8 antibodies and uses thereof
    Patent number: 8771685
    Abstract: The present invention concerns antibodies to Bv8 and the uses of same.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 8, 2014
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Xiumin Wu, Yan Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ching Liang, Yu-Ju G. Meng, Janet Tien
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
    Publication number: 20140178363
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: July 26, 2013
    Publication date: June 26, 2014
    Inventors: Napoleone FERRARA, Nina Korsisaari, Robert D. Mass
  • Inhibitors of angiopoietin-like 4 protein, combinations, and their use
    Patent number: 8604185
    Abstract: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: December 10, 2013
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Napoleone Ferrara, Xiao Huan Liang
  • EG-VEGF nucleic acids and polypeptides and methods of use
    Patent number: 8557238
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: October 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
  • Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3
    Patent number: 8541376
    Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: September 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
  • Compositions with Hematopoietic and Immune Activity
    Publication number: 20130195885
    Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
    Type: Application
    Filed: August 3, 2012
    Publication date: August 1, 2013
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer LeCouter
  • EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE
    Publication number: 20130189273
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Application
    Filed: May 6, 2011
    Publication date: July 25, 2013
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood, Theresa Shek
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20130178418
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: August 13, 2012
    Publication date: July 11, 2013
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
    Publication number: 20130028911
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: February 24, 2012
    Publication date: January 31, 2013
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • Vascular endothelial cell growth factor antagonists and uses thereof
    Patent number: 8287873
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: October 16, 2012
    Assignee: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Inhibitors of vascular endothelial growth factor activity
    Patent number: 8273353
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20120237514
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Applicant: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Compositions and methods for producing inhibitors of vascular endothelial growth factor activity
    Patent number: 8268591
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Methods for using inhibitors of vascular endothelial growth factor activity
    Patent number: 8268313
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Compositions with hematopoietic and immune activity
    Patent number: 8257702
    Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: September 4, 2012
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer LeCouter
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE THREATMENT OF EARLY STAGE TUMORS
    Publication number: 20120148584
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: February 22, 2012
    Publication date: June 14, 2012
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Nina Korsisaari, Robert D. Mass
  • Transgenic mice expressing humanized VEGF
    Patent number: 8110720
    Abstract: The present invention generally relates to humanized VEGF and non-human transgenic animals expressing it. The transgenic animals are also useful to study VEGF-related therapies.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc
    Inventor: Napoleone Ferrara
  • ANTI-BV8 ANTIBODIES AND USES THEREOF
    Publication number: 20120014941
    Abstract: The present invention concerns antibodies to Bv8 and the uses of same.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 19, 2012
    Inventors: Xiumin Wu, Yan Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ching Liang, Yu-Ju G. Meng, Janet Tien
  • Polypeptides Homologous to VEGF and BMP1
    Publication number: 20110319327
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: April 27, 2011
    Publication date: December 29, 2011
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo